Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

110.15 -1.00 (-0.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
67 68 Next >
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories
Benzinga Bitcoin Spiked On False ETF Approval Rumor 
Via Benzinga
Topics ETFs
Price Over Earnings Overview: BioNTech
Via Benzinga
A Look Into BioNTech Inc's Price Over Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 16, 2023
Via Benzinga
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Pfizer cut about $9 billion from its sales expectations for Covid products this year. 
Via Investor's Business Daily
Exposures COVID-19
Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry
Via Benzinga
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves. 
Via Benzinga
Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.  
Via Benzinga
Exposures COVID-19
Pfizer Cuts Annual Revenue Guidance By $9B Amid COVID-19 Vaccine Sales Slump, BioNTech Warns €900M Write-Offs
Friday, Pfizer Inc (NYSE: PFE) slashed its full-year earnings and revenue guidance, citing decreasing demand for its  
Via Benzinga
Exposures COVID-19
BioNTech, Moderna And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Cut Your Losses: Sell These 7 Weak Stocks Now
You can't let weakness in a company or the market damage your portfolio. Avoid disappointing returns by moving on these stocks to sell. 
Via InvestorPlace
Is Novavax Stock a Buy Now?
Is this company just a pandemic stock? 
Via The Motley Fool
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
From BioNTech SE
Via GlobeNewswire
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
From BioNTech SE
Via GlobeNewswire
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?
Vaccine revenue may have slipped but could still represent billions of dollars for these companies. 
Via The Motley Fool
Exposures COVID-19
7 Innovator Stocks Primed for Exceptional Growth
These featured, inventive companies are not only transforming old sectors but also building bridges toward new ones. 
Via InvestorPlace
Privatized Vaccine Distribution Sparks Confusion, Payment Challenges
As the rollout of the updated COVID-19 vaccine progresses, some individuals have been surprised by requests for upfront payments ranging from $150 to $200.  
Via Benzinga
Exposures COVID-19
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Why Novavax Stock Fell Today
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Wednesday amid a pullback in the stock, which gained Tuesday after the FDA granted Emergency Use Authorization for the company's updated... 
Via Benzinga
Exposures COVID-19 Product Safety
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock. 
Via Benzinga
Short Sellers Are Betting Against Novavax (NVAX) Stock
Shorts are betting no one will want Novavax's Covid-19 vaccine, but the pandemic is not yet over, and NVAX stock is cheap. 
Via InvestorPlace
Exposures COVID-19
Novavax Surges After FDA Signs Off On Its Updated Covid Shot, Joining Pfizer, Moderna
The company can now join Pfizer and Moderna in launching an updated booster in the U.S. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Novavax Stock Soars On FDA Clearance For Updated Covid-19 Shot: What's Going On?
Novavax Inc (NASDAQ: NVAX) shares are surging Tuesday afternoon after the U.S. 
Via Benzinga
Exposures COVID-19 Product Safety
Nobel Prize Honors Scientists Behind mRNA Vaccines Against Covid-19
Discover the remarkable journey of Nobel Prize laureates Kariko and Weissman, who transformed medicine with mRNA vaccines, and the financial impact on Moderna and Pfizer stocks. 
Via Benzinga
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street
Analysts like these stocks for very good reasons. 
Via The Motley Fool
Why Pfizer and BioNTech Stocks Zoomed Higher Today
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle. 
Via The Motley Fool
Exposures COVID-19
Why CureVac Stock Plunged Today
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech. 
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.